Until March 2020, Tim served as Chief Corporate Affairs Officer at Editas Medicine. He joined Editas in January 2016 and oversaw global policy, government affairs, corporate communications, market development, human resources, and culture initiatives. Tim is chair of the American Society of Gene and Cell Therapy’s Government Relations Committee and was a member of BIO’s Human Genome Editing Working Group (staff), the Alliance for Regenerative Medicine’s Gene Editing Task Force, and the Duke Margolis Center for Health Policy’s Advisory Group on Value-Based Payment for Medical Products. Prior to joining Editas, Tim served as Senior Vice President of Public Affairs for Cubist Pharmaceuticals, until the company was acquired by Merck in 2015. Before joining Cubist, Tim spent several years at Biogen Idec, where he served as Vice President of Public Affairs, overseeing global communications. He received his J.D. from the Columbus School of Law at the Catholic University of America and his B.A. in History and Philosophy from Boston College. He is a member of the board of directors of Life Sciences Cares and a strategic advisory board member at Spero Therapeutics.

In November of 2012, Monica's twin son, Beckett, was the first to be diagnosed at Texas Children's Genetics Clinic with the gene mutation SYNGAP1 (6p21.3). When Beckett was 4 months old, she noticed he was not meeting the same milestones as his twin sister. Monica then began a journey to find answers to help her son. She started to blog about his progress and this led to building a community of parents and caregivers that are now a strong support group. She is the Founder and President/CEO of Bridge the Gap – SYNGAP Education and Research Foundation. It is her passion to help support these families by raising awareness and creating a strong foundation that will accelerate a path to better therapies.

She retired in 2016 after 23 years in education teaching secondary science. Her new focus is on building the programs and mission of Bridge the Gap – SYNGAP Education and Research Foundation. She is the Primary Investigator on the SYNGAP1 (MRD5) Registry and Natural History Study. She is a life member of the Worldwide Association of Female Professionals and a member of the first class of 2017 Illumina Ambassadors established in the United States. In addition to leading the foundation, she is an author, public speaker, consultant on rare disease business strategies and advocates for rare disease legislation at both the federal and state levels. Several of her authored scientific publications include Nature Neuroscience, The Journal of Neurodevelopmental Disorders, and The Journal of Pediatrics. She has authored a book about her son Beckett’s diagnostic journey called “Slow Moving Stream - My Special Boy”. She is a graduate from East Texas Baptist University with a Bachelor's of Science in Biology/Psychology (1991) and Secondary Certification in Education (1995). She will be attending Northwestern University Pritzker School of Law in the Fall of 2020 to earn her Masters in Science Law. She has five beautiful children, Haleigh (28), Taylor, USMC (25), Sawyer (23), and the twins Beckett & Pyper (12). She was a Global Genes 2015 & 2016 RARE Champion in Advocacy Award nominee for her work in the rare disease community and Wego Health Awards Nominee for years 2015, 2017, 2018, & 2019. 2020 Global Shakers Rare Disease Champion.